Loading...

BlackRock Health Sciences Trust

NYSE:BME
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BME
NYSE
$364M
Market Cap
  1. Home
  2. US
  3. Diversified Financials
Company description

BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The last earnings update was 17 days ago. More info.


Add to Portfolio Compare Print
  • BlackRock Health Sciences Trust is a fund or ETF! Currently our data availability for these is poor, we only recommend using them as part of a portfolio.
BME Share Price and Events
7 Day Returns
-2.1%
NYSE:BME
-4.1%
US Capital Markets
-1.1%
US Market
1 Year Returns
13.4%
NYSE:BME
-10.7%
US Capital Markets
5.8%
US Market
BME Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BlackRock Health Sciences Trust (BME) -2.1% -3.2% 16.2% 13.4% 12.5% 5.8%
US Capital Markets -4.1% -4.6% 12.6% -10.7% 51.9% 54.1%
US Market -1.1% -0.2% 19.7% 5.8% 37.9% 41.7%
1 Year Return vs Industry and Market
  • BME outperformed the Capital Markets industry which returned -10.7% over the past year.
  • BME outperformed the Market in United States of America which returned 5.8% over the past year.

Value

 Is BlackRock Health Sciences Trust undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BlackRock Health Sciences Trust to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BlackRock Health Sciences Trust.

NYSE:BME Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Excess Returns Model
Stable EPS Median Return on Equity from the past 5 years.
= Stable Book Value * Return on Equity
= $35.69 * 8.8%
$3.16
Book Value of Equity per Share Median Book Value from the past 5 years. $35.69
Discount Rate (Cost of Equity) See below 7.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NYSE:BME
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Capital Markets Unlevered Beta Simply Wall St/ S&P Global 0.72
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.718 (1 + (1- 21%) (0%))
0.811
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.811 * 5.96%)
7.56%

Discounted Cash Flow Calculation for NYSE:BME using Excess Returns Model Model

The calculations below outline how an intrinsic value for BlackRock Health Sciences Trust is arrived at using the Excess Return Model. This approach is used for finance firms where free cash flow is difficult to estimate.

In the Excess Return Model the value of a firm can be written as the sum of capital invested currently in the firm and the present value of excess returns that the firm expects to make in the future.

The model is sensitive to the Return on Equity of the company versus the Cost of Equity, how these are calculated is detailed below the main calculation.

Note the calculations below are per share.

See our documentation to learn about this calculation.

NYSE:BME Value of Excess Returns
Calculation Result
Excess Returns = (Stable Return on equity – Cost of equity) (Book Value of Equity per share)
= (8.8% – 7.56%) * $35.69)
$0.46
Terminal Value of Excess Returns = Excess Returns / (Cost of Equity - Expected Growth Rate)
= $0.46 / (7.56% - 2.73%)
$9.43
Value of Equity = Book Value per share + Terminal Value of Excess Returns
= $35.69 + $9.43
$45.12
NYSE:BME Discount to Share Price
Calculation Result
Value per share (USD) From above. $45.12
Current discount Discount to share price of $39.17
= -1 x ($39.17 - $45.12) / $45.12
13.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BlackRock Health Sciences Trust is available for.
Intrinsic value
13%
Share price is $39.17 vs Future cash flow value of $45.12
Current Discount Checks
For BlackRock Health Sciences Trust to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BlackRock Health Sciences Trust's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • BlackRock Health Sciences Trust's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BlackRock Health Sciences Trust's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BlackRock Health Sciences Trust's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NYSE:BME PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $2.28
NYSE:BME Share Price ** NYSE (2019-03-25) in USD $39.17
United States of America Capital Markets Industry PE Ratio Median Figure of 78 Publicly-Listed Capital Markets Companies 25.27x
United States of America Market PE Ratio Median Figure of 3,061 Publicly-Listed Companies 17.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BlackRock Health Sciences Trust.

NYSE:BME PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:BME Share Price ÷ EPS (both in USD)

= 39.17 ÷ 2.28

17.16x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BlackRock Health Sciences Trust is good value based on earnings compared to the US Capital Markets industry average.
  • BlackRock Health Sciences Trust is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does BlackRock Health Sciences Trust's expected growth come at a high price?
Raw Data
NYSE:BME PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 17.16x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Capital Markets Industry PEG Ratio Median Figure of 33 Publicly-Listed Capital Markets Companies 1.85x
United States of America Market PEG Ratio Median Figure of 2,104 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BlackRock Health Sciences Trust, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BlackRock Health Sciences Trust's assets?
Raw Data
NYSE:BME PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $35.87
NYSE:BME Share Price * NYSE (2019-03-25) in USD $39.17
United States of America Capital Markets Industry PB Ratio Median Figure of 153 Publicly-Listed Capital Markets Companies 4.62x
United States of America Market PB Ratio Median Figure of 5,166 Publicly-Listed Companies 1.85x
NYSE:BME PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:BME Share Price ÷ Book Value per Share (both in USD)

= 39.17 ÷ 35.87

1.09x

* Primary Listing of BlackRock Health Sciences Trust.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BlackRock Health Sciences Trust is good value based on assets compared to the US Capital Markets industry average.
X
Value checks
We assess BlackRock Health Sciences Trust's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Capital Markets industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Capital Markets industry average (and greater than 0)? (1 check)
  5. BlackRock Health Sciences Trust has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BlackRock Health Sciences Trust expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BlackRock Health Sciences Trust has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
6.6%
Expected Capital Markets industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BlackRock Health Sciences Trust expected to grow at an attractive rate?
  • Unable to compare BlackRock Health Sciences Trust's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare BlackRock Health Sciences Trust's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare BlackRock Health Sciences Trust's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NYSE:BME Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Capital Markets Industry Earnings Growth Rate Market Cap Weighted Average 6.6%
United States of America Capital Markets Industry Revenue Growth Rate Market Cap Weighted Average 3.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NYSE:BME Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NYSE:BME Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 5 2 22
2018-09-30 4 5 28
2018-06-30 4 9 34
2018-03-31 4 4 47
2017-12-31 4 -1 60
2017-09-30 4 0 50
2017-06-30 3 1 39
2017-03-31 3 5 11
2016-12-31 3 10 -16
2016-09-30 3 25 -18
2016-06-30 3 41 -21
2016-03-31 3 40 6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if BlackRock Health Sciences Trust is high growth as no earnings estimate data is available.
  • Unable to determine if BlackRock Health Sciences Trust is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NYSE:BME Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from BlackRock Health Sciences Trust Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:BME Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 2.28
2018-09-30 2.86
2018-06-30 3.59
2018-03-31 5.01
2017-12-31 6.49
2017-09-30 5.33
2017-06-30 4.30
2017-03-31 1.25
2016-12-31 -1.88
2016-09-30 -2.14
2016-06-30 -2.51
2016-03-31 0.76

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BlackRock Health Sciences Trust will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BlackRock Health Sciences Trust's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BlackRock Health Sciences Trust has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BlackRock Health Sciences Trust performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BlackRock Health Sciences Trust's growth in the last year to its industry (Capital Markets).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BlackRock Health Sciences Trust's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • BlackRock Health Sciences Trust's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • BlackRock Health Sciences Trust's 1-year earnings growth is negative, it can't be compared to the US Capital Markets industry average.
Earnings and Revenue History
BlackRock Health Sciences Trust's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BlackRock Health Sciences Trust Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NYSE:BME Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4.53 22.44 3.88
2018-09-30 4.34 28.07 3.79
2018-06-30 4.14 33.70 3.71
2018-03-31 3.91 47.02 3.60
2017-12-31 3.67 60.34 3.49
2017-09-30 3.58 49.55 3.37
2017-06-30 3.49 38.76 3.25
2017-03-31 3.42 11.25 3.21
2016-12-31 3.35 -16.27 3.17
2016-09-30 3.31 -18.48 3.30
2016-06-30 3.27 -20.68 3.43
2016-03-31 3.24 6.30 3.54
2015-12-31 3.20 33.28 3.65
2014-12-31 3.19 50.35 3.50
2014-10-31 3.11 71.14 3.13
2014-07-31 3.26 60.76 3.04
2014-04-30 3.41 50.37 2.94
2014-01-31 3.52 59.86 2.83
2013-10-31 3.64 69.35 2.71
2013-07-31 3.51 60.61 2.60
2013-04-30 3.38 51.87 2.48
2013-01-31 3.18 42.00 2.42
2012-10-31 2.97 32.14 2.36
2012-07-31 2.90 17.39 2.36
2012-04-30 2.83 2.64 2.36

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • BlackRock Health Sciences Trust has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • BlackRock Health Sciences Trust used its assets more efficiently than the US Capital Markets industry average last year based on Return on Assets.
  • BlackRock Health Sciences Trust has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess BlackRock Health Sciences Trust's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Capital Markets industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BlackRock Health Sciences Trust has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BlackRock Health Sciences Trust's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BlackRock Health Sciences Trust's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BlackRock Health Sciences Trust's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • BlackRock Health Sciences Trust has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BlackRock Health Sciences Trust's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 179.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BlackRock Health Sciences Trust Company Filings, last reported 2 months ago.

NYSE:BME Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 352.67 0.00 0.00
2018-09-30 352.67 0.00 0.00
2018-06-30 342.73 0.00 0.42
2018-03-31 342.73 0.00 0.42
2017-12-31 331.86 0.13 0.00
2017-09-30 331.86 0.13 0.00
2017-06-30 317.54 0.00 0.04
2017-03-31 317.54 0.00 0.04
2016-12-31 270.69 0.13 0.21
2016-09-30 270.69 0.13 0.21
2016-06-30 279.03 0.16 0.00
2016-03-31 279.03 0.16 0.00
2015-12-31 297.53 0.00 0.00
2014-12-31 303.10 0.00
2014-10-31 313.93 0.00 0.00
2014-07-31 313.93 0.00 0.00
2014-04-30 272.18 0.29 0.14
2014-01-31 272.18 0.29 0.14
2013-10-31 270.16 0.00 0.00
2013-07-31 270.16 0.00 0.00
2013-04-30 247.41 0.00 0.05
2013-01-31 247.41 0.00 0.05
2012-10-31 218.38 4.19 0.00
2012-07-31 218.38 4.19 0.00
2012-04-30 212.81 6.30 0.01
  • BlackRock Health Sciences Trust's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (0.1% vs 0% today).
  • Debt is well covered by operating cash flow (43857.9%, greater than 20% of total debt).
  • Unable to confirm if the interest payments on BlackRock Health Sciences Trust's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess BlackRock Health Sciences Trust's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BlackRock Health Sciences Trust has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BlackRock Health Sciences Trust's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
6.13%
Current annual income from BlackRock Health Sciences Trust dividends.
If you bought $2,000 of BlackRock Health Sciences Trust shares you are expected to receive $123 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • BlackRock Health Sciences Trust's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.49%).
  • BlackRock Health Sciences Trust's dividend is above the markets top 25% of dividend payers in United States of America (3.72%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NYSE:BME Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Capital Markets Industry Average Dividend Yield Market Cap Weighted Average of 43 Stocks 2.1%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2003 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.9%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NYSE:BME Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-03-01 2.400 6.009
2019-02-01 2.400 5.960
2019-01-02 2.400 6.200
2018-12-31 2.400 6.481
2018-11-01 2.400 6.245
2018-10-01 2.400 5.946
2018-09-04 2.400 5.818
2018-08-01 2.400 5.905
2018-07-02 2.400 6.019
2018-06-01 2.400 6.277
2018-05-01 2.400 6.704
2018-04-02 2.400 6.900
2018-03-01 2.400 6.800
2018-02-01 3.000 8.683
2018-01-02 3.000 8.179
2017-12-08 3.000 8.303
2017-11-01 3.000 8.382
2017-10-02 3.000 8.213
2017-09-01 3.000 8.267
2017-08-01 3.000 8.351
2017-07-03 3.000 8.108
2017-06-01 3.000 8.383
2017-04-04 3.000 8.651
2017-02-01 3.000 8.823
2017-01-03 3.000 9.119
2016-12-07 3.000 9.220
2016-11-01 6.949 20.477
2016-10-03 6.949 20.727
2016-09-01 6.949 20.020
2016-08-01 6.949 19.629
2016-07-01 6.949 19.390
2016-06-01 6.949 19.459
2016-05-02 6.949 18.741
2016-04-01 6.949 18.834
2016-02-01 6.949 20.116
2016-01-05 6.949 18.910
2015-12-07 6.949 17.370
2015-11-02 4.770 11.410
2015-10-01 4.770 11.867
2015-09-01 4.770 11.391
2015-08-03 4.770 10.352
2015-06-01 4.350 9.904
2015-05-01 4.350 10.224
2015-04-02 4.350 10.175
2015-03-03 4.350 10.084
2015-02-02 4.350 10.604
2015-01-02 4.350 10.618
2014-12-08 1.980 4.711
2014-11-03 4.220 9.822
2014-10-01 2.830 7.347
2014-09-02 2.571 6.800
2014-06-02 1.720 4.736
2014-03-03 1.720 4.686
2013-09-03 2.388 6.926
2013-06-03 2.388 7.403
2013-03-01 2.388 7.650
2012-12-10 2.388 8.057
2012-09-04 2.501 8.915
2012-06-01 2.501 9.052
2012-03-01 2.501 9.198
2011-12-09 2.501 9.463
2011-09-01 1.538 6.100
2011-06-01 1.538 5.681
2011-03-01 1.538 5.566
2010-12-13 1.538 5.693
2010-09-02 1.538 5.884
2010-06-02 1.538 6.271
2010-03-01 1.538 5.879
2009-12-11 1.538 5.912
2009-09-01 1.538 6.491
2009-06-01 1.538 7.095
2009-03-26 1.538 7.844

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of BlackRock Health Sciences Trust's earnings are paid to the shareholders as a dividend.
  • Dividends paid are not well covered by earnings (1x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BlackRock Health Sciences Trust's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BlackRock Health Sciences Trust afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BlackRock Health Sciences Trust has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BlackRock Health Sciences Trust's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Perlowski
AGE 54
TENURE AS CEO 8.2 years
CEO Bio

Mr. John M. Perlowski, CPA served the Chief Executive Officer, President and Chief Financial Officer of BlackRock Science and Technology Trust. Mr. Perlowski served as the Chief Financial Officer and President of Blackrock Utility & Infrastructure Trust. Mr. Perlowski served as the President and Chief Executive Officer of various funds in BlackRock Fund Complex and also served as its Managing Director. He served as the President at BlackRock Floating Rate Income Strategies Fund, Inc. He served as the Chief Executive Officer and President of Blackrock Real Asset Equity Trust, The BlackRock Pennsylvania Strategic Municipal Trust, BlackRock Dividend Income Trust and BlackRock Income Opportunity Trust, Inc. He served as the Chief Executive Officer at BlackRock MuniYield Investment Fund. He has management responsibility for the Goldman Sachs Asset Management (GSAM) Global Fund Services organization which is composed of the Transfer Agent and Fund Treasury functions. Mr. Perlowski served as Chief Financial Officer of various funds in BlackRock Fund Complex. He served as an Executive Officer of Goldman Sachs Group Inc. He joined Goldman Sachs in July 1995. He served as the Managing Director, Principal Financial Officer, Chief Operating Officer, Senior Vice President, Treasurer and Vice President of various funds in the fund complex of Goldman Sachs Trust. Mr. Perlowski served as Fund Accounting/Custody Manager of Investors Bank and Trust Company. He served as a Manager in the Financial Services Division at Arthur Andersen & Co. until 1993. Mr. Perlowski serves as a Trustee of BlackRock Science and Technology Trust. He serves as a Sole Initial Trustee of Blackrock Utility & Infrastructure Trust. He served as Trustee of various funds in BlackRock Fund Complex. He served as a Director at Goldman Sachs Administration Services Company Limited until October 15, 2009. He served as a Director of Goldman Sachs Global Alpha Fund from May 27, 2004 to October 15, 2009. He served as a Director of Goldman Sachs Offshore Funds from 2002 to 2009. Mr. Perlowski became a Certified Public Accountant in 1988 and holds BBA degree from the University of Notre Dame in 1986.

CEO Compensation
  • Insufficient data for John to compare compensation growth.
  • Insufficient data for John to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the BlackRock Health Sciences Trust management team in years:

8.2
Average Tenure
48
Average Age
  • The average tenure for the BlackRock Health Sciences Trust management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

John Perlowski

TITLE
Chief Executive Officer and President
AGE
54
TENURE
8.2 yrs

Neal Andrews

TITLE
Chief Financial Officer
AGE
52
TENURE
12.2 yrs

Charles Choon Park

TITLE
Chief Compliance Officer and Anti-Money Laundering Officer
AGE
51
TENURE
5.2 yrs

Michael Carey

TITLE
Managing Director and Portfolio Manager

Jay Fife

TITLE
Treasurer
AGE
48
TENURE
12.2 yrs

Janey Ahn

TITLE
Secretary
AGE
43
TENURE
7.2 yrs

Brendan Kyne

TITLE
Vice President
AGE
41
TENURE
10.2 yrs

Robert Crothers

TITLE
Vice President
AGE
37
TENURE
7.2 yrs

Tom Callan

TITLE
Portfolio Manager

Kyle McClements

TITLE
Portfolio Manager
Board of Directors Tenure

Average tenure and age of the BlackRock Health Sciences Trust board of directors in years:

17.7
Average Tenure
71
Average Age
  • The average tenure for the BlackRock Health Sciences Trust board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Richard Cavanagh

TITLE
Chairman
COMPENSATION
$3K
AGE
72

Karen Robards

TITLE
Vice Chairman of the Board
COMPENSATION
$3K
AGE
68

Jerrold Harris

TITLE
Independent Trustee
COMPENSATION
$2K
AGE
76
TENURE
20.2 yrs

Robert Hubbard

TITLE
Independent Trustee
COMPENSATION
$2K
AGE
59
TENURE
15.2 yrs

Kathleen Feldstein

TITLE
Independent Trustee
COMPENSATION
$2K
AGE
77
TENURE
14.2 yrs

James Flynn

TITLE
Independent Trustee
COMPENSATION
$2K
AGE
79
TENURE
23.2 yrs

W. Kester

TITLE
Independent Trustee
COMPENSATION
$2K
AGE
67
TENURE
21.2 yrs

Frank Fabozzi

TITLE
Independent Trustee
COMPENSATION
$2K
AGE
70
TENURE
31.2 yrs

Mike Castellano

TITLE
Independent Trustee
COMPENSATION
$2K
AGE
72
TENURE
7.9 yrs

Paul Audet

TITLE
Interested Trustee
AGE
64
TENURE
7.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess BlackRock Health Sciences Trust's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BlackRock Health Sciences Trust has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services. It also invests through equity derivatives, with an emphasis on option writing. The fund benchmarks the performance of its portfolio against the Russell 3000 Healthcare Index. BlackRock Health Sciences Trust was formed on March 31, 2005 and is domiciled in the United States.

Details
Name: BlackRock Health Sciences Trust
BME
Exchange: NYSE
Founded: 2005
$364,329,100
9,301,228
Website: http://www.blackrock.com/investing/products/240227/blackrock-health-sciences-trust-usd-fund
Address: BlackRock Health Sciences Trust
100 Bellevue Parkway,
Wilmington,
Delaware, 19809,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE BME Common Shares New York Stock Exchange US USD 29. Mar 2005
Number of employees
Current staff
Staff numbers
0
BlackRock Health Sciences Trust employees.
Industry
Asset Management and Custody Banks
Diversified Financials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/25 23:59
End of day share price update: 2019/03/25 00:00
Last earnings filing: 2019/03/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.